MAM
CORT icon

Milestone Asset Management’s Corcept Therapeutics CORT Stock Holding History

Milestone Asset Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-51,599
Closed -$1.68M – 205
2024
Q2 		$1.68M Buy
51,599
+16,593
+47% +$455K 0.42% 47
2024
Q1 		$882K Buy
+35,006
New +$827K 0.25% 80

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Milestone Asset Management's CORT Position: Q3 2024 in Review

Milestone Asset Management sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 51,599 shares — an estimated $1.68M sold.

Milestone Asset Management first reported a position in CORT in Q1 2024 and held it in 2 quarters. The position peaked at $1.68M in Q2 2024. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • Milestone Asset Management reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Milestone Asset Management sold 51,599 Corcept Therapeutics shares in Q3 2024, an estimated $1.68M.
  • Milestone Asset Management first reported a position in Corcept Therapeutics in Q1 2024 and held it in 2 quarters.
  • Milestone Asset Management's Corcept Therapeutics position peaked at $1.68M in Q2 2024.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on Milestone Asset Management's 13F filing for Q3 2024, filed 25 Oct 2024.